ADRX ADARX PHARMACEUTICALS INC
FollowCommon Stock, par value $0.0001 per share (common), issuer CIK 1802369
No 13F filer reports this security in the loaded quarters.
13D and 13G filers
Each filer's latest stake. The shares are the aggregate the reporting persons state, which can include entities that file no 13F.
- ORBIMED ADVISORS LLC(group ORBIMED ADVISORS LLC)
14,913,764 shares, 14% in a 13D as of 2026-09-28,0000947871-26-000917
Accepted , ingested - SR ONE CAPITAL MANAGEMENT, LLC(group SR ONE CAPITAL MANAGEMENT, LLC)
9,936,661 shares, 9.3% in a 13D as of 2026-09-28,0001072613-26-000820
Accepted , ingested - BCLS Fund III Investments, LP(group BCLS II Investco, LP)
6,728,970 shares, 6.3% in a 13G as of 2026-09-24,0001193125-26-410626
Accepted , ingested
Insider trades
No Form 4 transaction on this security in the data.
Events
SR ONE CAPITAL MANAGEMENT, LLC and 9 other reporting persons reported 9,936,661 ADRX shares, 9.3% of the class, as of 2026-09-28, in a 13D filed 2026-10-05. 0001072613-26-000820
Accepted , ingestedORBIMED ADVISORS LLC and 4 other reporting persons reported 14,913,764 ADRX shares, 14% of the class, as of 2026-09-28, in a 13D filed 2026-10-02. 0000947871-26-000917
Accepted , ingestedBCLS Fund III Investments, LP reported 6,728,970 ADRX shares, 6.3% of the class, as of 2026-09-24, in a 13G filed 2026-10-01. 0001193125-26-410626
Accepted , ingested